The experimental treatment, known as Rina-S, met its primary endpoint of progression-free survival while simultaneously hitting a critical secondary goal by improving overall survival rates. These results provide a strong clinical foundation for the drug's potential path toward market approval.

Following the announcement, Genmab shares climbed 6.8% to reach $42.73 by midday Friday, extending the stock's annual gains to 39%. CEO Jan van de Winkel characterized the findings as a major step toward establishing the firm as a leader in gynecologic oncology. The company is now preparing to initiate discussions with global regulatory authorities to determine the necessary requirements for filing and commercialization.